Company / Financials
TriSalus Life Sciences, Inc. Financials
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$29.4M
FY2025 · +59.0% YoY
Net Income
-$30.0M
FY2025 · +49.4% YoY
Profit Margin
-102.1%
FY2025 · net income / revenue
ROE
-
FY2025 · return on equity
Total Assets
$35.3M
FY2025
Total Debt
$33.0M
-1.28x debt/equity
Equity
-$25.9M
FY2025
ROA
-85.0%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -2.11 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$29.4M+59.0% YoYNet Income HistoryProfit after all expenses and taxes-$30.0M+49.4% YoYGross Profit HistoryRevenue minus cost of goods sold$25.3M+59.2% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$4.1M+57.5% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$36.2M+33.6% YoYSG&A Expense HistorySelling, general, and administrative expenses$18.0M-23.6% YoYR&D Expense HistoryResearch and development spending$17.7M-40.7% YoYInterest Expense HistoryCost of borrowing and debt obligations$1.0KIncome Tax HistoryTotal income tax expense$6.0K-33.3% YoYEPS (Basic) HistoryBasic earnings per share-$1.31+80.6% YoY